130 related articles for article (PubMed ID: 32324525)
1. Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer
Liu L; Zhang J; Gu M; Li G; Ni J; Fan M
Anticancer Agents Med Chem; 2020; 20(14):1722-1727. PubMed ID: 32324525
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of regulated cycle inhibiting factors induced upon Tet-On system in human colon cancer cell lines.
Liu L; Ni J; Zhang J; He X
Anticancer Drugs; 2018 Oct; 29(9):854-860. PubMed ID: 29923895
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
4. A Salmonella Typhimurium mutant strain capable of RNAi delivery: higher tumor-targeting and lower toxicity.
Cheng X; Zhang X; Zhou Y; Zhang C; Hua ZC
Cancer Biol Ther; 2014 Aug; 15(8):1068-76. PubMed ID: 24842165
[TBL] [Abstract][Full Text] [Related]
5. Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct.
Zhao C; He J; Cheng H; Zhu Z; Xu H
J Exp Clin Cancer Res; 2016 Jul; 35(1):107. PubMed ID: 27371094
[TBL] [Abstract][Full Text] [Related]
6. Proteomic screening of anaerobically regulated promoters from Salmonella and its antitumor applications.
Chen J; Wei D; Zhuang H; Qiao Y; Tang B; Zhang X; Wei J; Fang S; Chen G; Du P; Huang X; Jiang W; Hu Q; Hua ZC
Mol Cell Proteomics; 2011 Jun; 10(6):M111.009399. PubMed ID: 21474796
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009.
Li M; Lu M; Lai Y; Zhang X; Li Y; Mao P; Liang Z; Mu Y; Lin Y; Zhao AZ; Zhao Z; Zhou S; Li F
Biomed Pharmacother; 2020 Sep; 129():110425. PubMed ID: 32570123
[TBL] [Abstract][Full Text] [Related]
9. Toxicology and efficacy of tumor-targeting
Zhang Y; Cao W; Toneri M; Zhang N; Kiyuna T; Murakami T; Nelson SD; Dry SM; Li Y; Li S; Wang X; Ma H; Singh AS; Eilber FC; Hoffman RM; Zhao M
Oncotarget; 2017 Aug; 8(33):54616-54628. PubMed ID: 28903369
[No Abstract] [Full Text] [Related]
10. Tumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma.
Liu Z; Liu X; Cao W; Hua ZC
Am J Cancer Res; 2015; 5(2):792-801. PubMed ID: 25973316
[TBL] [Abstract][Full Text] [Related]
11. [Anti-tumor effect and impact on tumor immune microenvironment of tumor-targeted Salmonella VNP20009].
Han YH; Lai XH; Le ZW; Hua ZC
Yao Xue Xue Bao; 2016 Sep; 51(9):1417-22. PubMed ID: 29924525
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific delivery of histidine-rich glycoprotein suppresses tumor growth and metastasis by anti-angiogenesis and vessel normalization.
Cheng X; Zhang X; Cheng W; Chen J; Ma C; Yang B; Hua ZC
Curr Gene Ther; 2014; 14(2):75-85. PubMed ID: 24606115
[TBL] [Abstract][Full Text] [Related]
13. Bacteria-mediated tumor-targeted delivery of tumstatin (54-132) significantly suppresses tumor growth in mouse model by inhibiting angiogenesis and promoting apoptosis.
Bao F; Liu M; Gai W; Hua Y; Li J; Han C; Zai Z; Li J; Hua Z
Front Med; 2022 Dec; 16(6):873-882. PubMed ID: 36152127
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
15. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies.
Bereta M; Hayhurst A; Gajda M; Chorobik P; Targosz M; Marcinkiewicz J; Kaufman HL
Vaccine; 2007 May; 25(21):4183-92. PubMed ID: 17399861
[TBL] [Abstract][Full Text] [Related]
16. Microwave ablation combined with attenuated Salmonella typhimurium for treating hepatocellular carcinoma in a rat model.
Zhao Q; Qu X; Liu K; Shi H; Yang G; Zhou B; Zhu L; Zhang W; Yan Z; Liu R; Qian S; Wang J
Oncotarget; 2017 Jul; 8(29):47655-47664. PubMed ID: 28498813
[TBL] [Abstract][Full Text] [Related]
17. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.
Chen J; Yang B; Cheng X; Qiao Y; Tang B; Chen G; Wei J; Liu X; Cheng W; Du P; Huang X; Jiang W; Hu Q; Hu Y; Li J; Hua ZC
Cancer Sci; 2012 Feb; 103(2):325-33. PubMed ID: 22054098
[TBL] [Abstract][Full Text] [Related]
18. Effect of Salmonella enterica serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression.
Coutermarsh-Ott SL; Broadway KM; Scharf BE; Allen IC
Oncotarget; 2017 May; 8(20):33601-33613. PubMed ID: 28431394
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Salmonella VNP20009 mutant (ΔhtrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency.
Xu W; Zhou T; Zhou J; Qiang Z; Zhang J; Hua Z
Lett Appl Microbiol; 2018 Jul; 67(1):97-103. PubMed ID: 29698572
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
